Synthesis of omecamtiv mecarbyl

Abstract

FIELD: pharmaceutical chemistry.SUBSTANCE: methods for synthesizing intermediate compounds used in the synthesis of omecamtiv mecarbil. A method for synthesizing 2-fluoro-3-nitrotoluene (FNT) comprises mixing 2-fluorotoluene with one or more bases and a borating reagent to form a boronic acid and mixing the resulting boronic acid with iron nitrate or its hydrate to form FNT.EFFECT: reproducible and efficient production of FNT and other intermediate compounds applicable for the production of omecamtiv mecarbil.44 cl, 4 dwg, 2 tbl, 4 ex

Description

Cross-reference to related applications

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 159,227, filed March 10, 2021, the disclosure of which is incorporated herein by reference in its entirety for all purposes.Background Art

[0002] The cardiac sarcomere is the basic unit of muscle contraction in the heart. The cardiac sarcomere is a highly ordered cytoskeletal structure composed of cardiac myosin, actin, and a set of regulatory proteins. The discovery and development of small-molecule activators of cardiac myosin may lead to promising treatments for acute and chronic heart failure, dilated cardiomyopathy (DCM), and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. Cardiac myosin is a cytoskeletal motor protein in cardiac muscle cells. It is directly responsible for converting chemical energy into mechanical force, resulting in cardiac muscle contraction.

[0003] Existing positive inotropic agents, such as beta-adrenergic receptor agonists or phosphodiesterase inhibitors, increase intracellular calcium concentrations, thereby enhancing cardiac sarcomere contractility. However, elevated calcium levels increase cardiac contractility and shorten systolic ejection time, which is associated with potentially life-threatening side effects. In contrast, cardiac myosin activators directly stimulate the activity of the cardiac myosin motor protein without increasing intracellular calcium concentrations. They accelerate the rate-limiting stage of the myosin enzymatic cycle and shift it toward a force-producing state.Instead of increasing heart rate, this mechanism prolongs systolic ejection time, resulting in increased cardiac contractility and cardiac output in a potentially more oxygen-efficient manner.

[0004] U.S. Patent No. 7,507,735, incorporated herein by reference, discloses a class of compounds, including omecamtiv mecarbil (AMG 423, CK-1827452) (herein "OM"), having the structure: OM is a first-in-class direct activator of cardiac myosin, the motor protein that causes heart contraction. It is being evaluated as a potential treatment for heart failure with both intravenous and oral formulations, with the goal of creating a new, continuous approach to patient care in both inpatient and outpatient settings. OM dihydrochloride hydrate is used as an oral formulation for the treatment of heart failure. Specific conditions include, but are not limited to, acute (or decompensated) congestive heart failure and chronic congestive heart failure, particularly those associated with systolic dysfunction. Methods for producing OM are disclosed in WO 2014 / 152270 (“'270 WO publication”) and WO 2019 / 006231 (“'231 WO publication”). Scheme 1. WO 2014 / 152270 Method for OM

[0006] The method for producing OM, which is disclosed in WO 2014 / 152270, is summarized in Scheme 1. The method disclosed in the '270 WO publication involves the preparation of the regulatory starting materials API piperazine nitro (PIPN) HCl and phenyl carbamate (PCAR) HCl, from commercially available raw materials, 2-fluoro-3-nitrotoluene (FNT) and 5-amino-2-methylpyridine (APYR). PIPN is further used with other improved intermediates to produce OM. The method of the '270 WO publication involves the use of a free base intermediate PMEC. Although free base PMEC is commercially available as an oil, it contains varying amounts of piperazine, which leads to the formation of an undesirable impurity BISN in the PIPN product, as shown in Scheme 2.Scheme 2.

[0007] The method disclosed in '231 WO publication describes a commercial method for producing OM, comprising a method using a stable crystalline salt of PMEC (i.e., PMEC phosphate hydrate) with a low and constant level of piperazine (Scheme 3). Scheme 3. WO 2019006231 Method for OM

[0008] The methods for producing OM disclosed in WO '270 and WO '231 publications use FNT as a starting material. FNT is a raw material that is currently prepared from 2-fluorotoluene using a short synthetic sequence. A disadvantage of this method is the need for a fractional distillation step of the mixture of resulting isomers to obtain the desired regioisomer, 2-fluoro-3-nitrotoluene, of acceptable purity, containing no more than 0.5% of any other isomers, as determined by gas chromatography. Moreover, the desired FNT regioisomer is obtained in less than 10% yield by this method.

[0009] In connection with the above, there is a need for a reproducible, efficient production of FNT and other compounds applicable for the manufacture of OM. The essence of the invention

[0010] The present invention relates to methods for synthesizing 2-fluoro-3-nitrotoluene (FNT) comprising (a) mixing 2-fluorotoluene with one or more bases and a borating reagent to form a boronic acid; and (b) mixing the resulting boronic acid with iron nitrate or its hydrate to form FNT.

[0011] The present invention also relates to methods for synthesizing FNT, comprising (a) mixing 2-fluorotoluene with one or more bases and a borating reagent to form a boronic acid; and (b) mixing the resulting boronic acid with nitric acid to form FNT.

[0012] The present invention further relates to a method for synthesizing 1-(bromomethyl)-2-fluoro-3-nitrobenzene (FNB), comprising (a) mixing 2-fluoro-3-nitrotoluene (FNT) with a brominating agent in the presence of a blue LED indicator to form a mixture of FNB and 1-(dibromomethyl)-2-fluoro-3-nitrobenzene (FNBr2); (b) mixing the FNB / FNBr2 mixture with a dialkyl phosphite to form FNB; and (c) optionally purifying the FNB formed in step (b) by (i) washing the FNB with a dialkyl phosphite and a trialkylamine or (ii) extracting the FNB with an organic solvent and washing with an aqueous base.Brief description of the drawings

[0013] Figure 1 is a diagram of a setup for producing LDA using a flow chemical process in Example 2-1.

[0014] Figure 2 is a diagram of a plant for borylation of 2-fluorotoluene by a flow chemical process in Example 2-1.

[0015] Figure 3 is a diagram of a plant for producing PIPN HBr from FNT using a flow chemical process as described in Example 3.

[0016] Figure 4 is a graph showing a summary of the collected fraction concentration data for a crude PIPN stream in the production of PIPN HBr from FNT using a flow chemistry process as described in Example 3. Detailed Description of the Invention

[0017] This document provides methods for producing FNT and other compounds useful in the manufacture of OM, as well as its salts and hydrates (e.g., OM dihydrochloride monohydrate). In some embodiments, the present invention relates to methods for preparing starting materials and intermediates used in commercial processes for producing OM dihydrochloride monohydrate.

[0018] In some embodiments, the disclosed methods are carried out in a batch mode (i.e., "batch chemistry"). In other embodiments, the disclosed methods are carried out using continuous manufacturing methods (i.e., using a "flow chemistry" or "continuous chemistry"). As used herein, continuous manufacturing refers to an integrated system of individual operations with a constant flow (continuous or intermittent). The disclosed methods using continuous chemistry can provide for the production of grams to metric tons of active pharmaceutical ingredients (APIs). In other cases, the disclosed methods involve a combination of steps carried out using batch chemistry and steps carried out using continuous chemistry. Method for Synthesizing FNT

[0019] The disclosure provides methods for producing FNT. In some embodiments, methods for synthesizing FNT comprise (a) mixing 2-fluorotoluene with one or more bases and a borating reagent to form a boronic acid; and (b) mixing the resulting boronic acid with iron nitrate or a hydrate thereof to form FNT. Alternatively, in some embodiments, the present invention relates to methods for producing FNT, wherein step (a) is as described above, and step (b) is mixing the resulting boronic acid with nitric acid to form FNT. Exemplary embodiments of the method are shown in Schemes 4A and 4B, wherein the method depicted in Scheme 4A illustrates a batch process, and the method depicted in Scheme 4B provides for a continuous manufacturing method (e.g., a flow chemical process method). Scheme 4A-B:

[0020] The disclosed methods provide a number of advantages over previous methods for producing FNT from 2-fluorotoluene, which is a readily available and relatively inexpensive starting material. For example, the boronation reaction of 2-fluorotoluene contributes to improved regioselectivity of the methods. The disclosed methods advantageously provide selective nitration of 2-fluorotoluene, offering a more regiospecific method for producing FNT with minimal byproducts compared to previous methods, thereby eliminating the fractional distillation step to obtain the desired regioisomer. In some embodiments, FNT is further purified, for example, by simple distillation or crystallization (e.g., in aqueous methanol). Further purification of FNT obtained by the disclosed methods is simplified since it produces minimal byproducts (e.g., undesired regioisomers).

[0021] Further, the disclosed methods provide an increased yield of FNT compared to previous methods that use 2-fluorotoluene as a starting material, which provide an FNT yield of only about 10%. In some embodiments, the disclosed methods provide FNT in an overall yield from 2-fluorotoluene of greater than 10%, such as 15%, 20%, 25%, 30%, 35%, 40%, or more. Reasons

[0022] The disclosed methods involve using one or more bases in the boration reaction (i.e., in step (a)). In step (a), any suitable base can be used, for example, an organic base. In some embodiments, the one or more bases comprise lithium diisopropylamide (LDA), which can be formed by deprotonation of diisopropylamine (DIPA), for example, with n-butyl lithium.

[0023] In some embodiments, in combination with other above or below embodiments, the disclosed methods further comprise treating the product obtained in step (b) with a second base. In these embodiments, the second base can comprise any suitable base capable of neutralizing any excess acid. Suitable second bases include, for example, alkaline hydroxides (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, rubidium hydroxide, cesium hydroxide, magnesium hydroxide, calcium hydroxide, strontium hydroxide, barium hydroxide, tetramethylammonium hydroxide, and combinations thereof. In some embodiments, the second base comprises sodium hydroxide (NaOH) (e.g., aqueous NaOH). The borylation reaction

[0024] The disclosed methods for producing FNT involve a borylation reaction to form a boronic acid using a borating reagent. The borating reagent can be a suitable borating reagent. Suitable borating reagents include, for example, trialkyl borates. In some embodiments, the borating reagent comprises trimethyl borate (MeO)3B. In some embodiments, the borating reagent comprises triethyl borate (EtO)3B.

[0025] In some embodiments, in combination with other embodiments described herein, the LDA borylation step is carried out as a flow chemistry step. Solvents

[0026] In some embodiments, the methods disclosed herein are carried out in one or more suitable solvents. Illustrative suitable solvents include, for example, polar aprotic solvents, polar protic solvents, and non-polar solvents. Suitable polar aprotic solvents include, for example, tetrahydrofuran, 1,2-dichloroethane (DCE), acetonitrile (MeCN), and a mixture thereof. Suitable non-polar solvents include, for example, cyclohexane, pentanes, hexanes, benzene, toluene, diethyl ether, and a combination thereof. Suitable polar protic solvents include, for example, alcohols (e.g., methanol).

[0027] In some embodiments, in combination with other above or below embodiments, step (a) is carried out in a solvent comprising a polar aprotic solvent (e.g., tetrahydrofuran).

[0028] In combination with other embodiments above or below, in some embodiments, step (b) is carried out in a solvent comprising a non-polar solvent (e.g., cyclohexane).

[0029] In some embodiments, in combination with other above or below embodiments, step (b) is carried out in a solvent comprising a polar aprotic solvent (e.g., DCE). In some embodiments where step (b) is carried out in DCE, DCE is present in an amount of 10 volumes to the boronic acid reactant.

[0030] In some embodiments, in combination with other embodiments above or below, the disclosed methods comprise a solvent change in which one or more additional solvents are introduced into the reaction vessel. In some embodiments, the one or more additional solvents substantially replace the solvent present prior to the introduction of the one or more solvents. As an example, in some embodiments of the nitration reaction disclosed herein, the nitration reaction is carried out in a solvent comprising 1,2-dichloroethane, and during the reaction, a solvent change is performed such that methanol is introduced into the organic phase. The nitration reaction

[0031] The disclosed methods for producing FNT include nitrating a boronic acid to form FNT. In some embodiments, the disclosed methods include mixing a boronic acid with iron nitrate or a hydrate thereof to form FNT. In some embodiments, the iron nitrate is hydrated. In some embodiments, the iron nitrate is characterized by the formula Fe(NO3)3 XH2O, where X is an integer of 1-9. In some embodiments, the iron nitrate is characterized by the formula Fe(NO3)3 9H2O.

[0032] In some embodiments, in combination with other embodiments above or below, the disclosed methods involve mixing a boronic acid with nitric acid to form FNT. In embodiments involving nitration using nitric acid, the concentration of nitric acid can be any suitable concentration. In some embodiments, the concentration of nitric acid is 70% or more aqueous (e.g., 80% or more or 90% aqueous). In some embodiments, the disclosed methods involve mixing the boronic acid with nitric acid while heating the reaction mixture. For example, the reaction mixture is heated to 50 ° C or more (eg 55 ° C, 60 ° C, 65 ° C, 70 ° C, 75 ° C or 80 ° C or more).

[0033] Furthermore, in some embodiments, in combination with other above or below embodiments, the reaction mixture is heated for at least 8 hours. In some embodiments, the reaction mixture is heated to 50 ° C or more for at least 8 hours. In some embodiments, the reaction mixture is heated to 60 ° C or more for at least 8 hours. In some embodiments, the reaction mixture is heated to 70 ° C or more for at least 8 hours. In some embodiments, the reaction mixture is heated to 80 ° C or more for at least 8 hours. In various cases, the reaction mixture is heated for 8 hours to 24 hours (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours). In some embodiments, the reaction mixture is heated for 8 hours to 12 hours.

[0034] In some embodiments, in combination with other embodiments described above or below, the method further comprises adding water to the reaction mixture. For example, in some embodiments, 10 volumes of water are added relative to the boronic acid reactant. Furthermore, in some embodiments, the organic phase is washed with an aqueous base solution (e.g., sodium bicarbonate). Furthermore, in some embodiments, one or more additional organic solvents are added (e.g., solvent exchange) to facilitate product isolation.

[0035] In some embodiments, the solvent is removed by distillation (e.g., vacuum distillation under reduced pressure). As an example, in some embodiments, the solvent containing 1,2-dichloroethane is removed by vacuum distillation under reduced pressure (e.g., 35 Torr).

[0036] The crude FNT is purified by any suitable method. In some embodiments, in combination with other above or below embodiments, the FNT is crystallized from methanol / water. In some embodiments, in combination with other above or below embodiments, the FNT is purified by fractional distillation at 110-120°C.

[0037] In some embodiments, in combination with other embodiments described herein, the nitration reaction is carried out in a batch mode after the borylation reaction carried out in a continuous manufacturing process. Compounds useful for producing OM

[0038] In various embodiments, the present invention relates to methods for preparing intermediates useful for producing OM (e.g., FNT, FNB, PIPN or a salt thereof, PMEC, PCAR, and / or PIPA), wherein the synthesis of the intermediates involves the use of FNT. In some embodiments, FNT is prepared according to the methods described herein.FNB

[0039] In some embodiments, the present invention relates to a method for synthesizing 1-(bromomethyl)-2-fluoro-3-nitrobenzene: (FNB). In various embodiments, in combination with other above or below embodiments, the disclosed methods for synthesizing FNB comprise mixing FNT with a brominating agent in the presence of a blue LED indicator to form a mixture of FNB and the dibromide compound, 1-(dibromomethyl)-2-fluoro-3-nitrobenzene (FNBr2), where the FNB / FNBr2 mixture is mixed with a dialkyl phosphite to form FNB.

[0040] As used in this document, "blue LED" refers to light emitted at a wavelength between 400 nm and 460 nm (e.g., 435-445 nm). The illustrative blue LED is commercially available from MilliporeSigma (St. Louis, MO) with an LED ring (IP68) with a wavelength of 435-445 nm.

[0041] In some embodiments, the disclosed method further comprises further purification of FNB, such as by additional washing and / or extraction methods. As an example, in some embodiments, FNB is further purified by washing FNB with a dialkyl phosphite and a trialkylamine base or by extracting FNB with an organic solvent and washing with an aqueous base. In some embodiments, the organic solvent is toluene. In some embodiments, the aqueous base is aqueous sodium hydroxide.

[0042] In various embodiments, the FNT used to produce FNB is produced in accordance with the methods disclosed herein.

[0043] The brominating agent may be any suitable brominating agent. In some embodiments, the brominating agent is N-bromosuccinimide (NBS).

[0044] The dialkyl phosphite may be any suitable dialkyl phosphite. In some embodiments, the dialkyl phosphite is selected from the group consisting of dimethyl phosphite, diethyl phosphite, and combinations thereof. In some embodiments, the dialkyl phosphite is diethyl phosphite.

[0045] In various embodiments, the disclosed methods for producing FNB further comprise converting FNB into other compounds suitable for producing omecamtiv mecarbil.PIPN or a salt thereof

[0046] In some embodiments, the present invention relates to methods for producing methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate (PIPN) or its salts. Illustrative salts of PIPN include the hydrobromide, hydrochloride, and mixtures thereof. In some embodiments, PIPN is prepared and / or isolated as the hydrobromide salt. PIPN - Photochemical Bromination

[0047] In some embodiments, the present invention relates to methods for producing PIPN or a salt thereof that comprise a photochemical bromination reaction. For example, the present invention relates to methods for synthesizing PIPN or a salt thereof from FNB prepared according to the photochemical methods described herein. In various embodiments, the methods comprise mixing FNB, a trialkylamine base, and piperazine methyl carboxylate ("PMEC") phosphate hydrate to form PIPN or its salt.

[0048] The trialkylamine base used herein may be any suitable trialkylamine base. Illustrative suitable trialkylamine bases include, for example, diisopropylethylamine (i.e., Hunig's base), trimethylamine, and mixtures thereof. PIPN - Free Radical Bromination

[0049] In some embodiments, the present invention relates to methods for producing PIPN or a salt thereof from FNT produced as described herein, wherein the bromination reaction is free-radical bromination. For example, in some embodiments, the disclosed methods comprise mixing FNT, benzoyl peroxide, NBS, and acetic acid at a temperature of 70-95°C to form FNB; optionally extracting FNB with toluene, washing FNB with an aqueous basic solution, or both; and mixing FNB, a trialkylamine base, and PMEC phosphate hydrate to form PIPN or a salt thereof.

[0050] In some embodiments, in combination with other above or below embodiments, the methods further comprise purifying the formed FNB before further transformations. For example, in some embodiments, the methods further comprise extracting the FNB formed with toluene and washing with aqueous sodium hydroxide before mixing with a trialkylamine base and PMEC phosphate hydrate. Furthermore, in some embodiments, the methods further comprise washing the formed FNB with aqueous sodium thiosulfate and aqueous sodium chloride before mixing with a trialkylamine base and PMEC phosphate hydrate.

[0051] Regardless of whether the bromination reaction is catalyzed by photochemical or free radical means, it is desirable to minimize the amount of FNBr2 formed. In some embodiments, in combination with other above or below embodiments, before mixing FNB, a trialkylamine base, and PMEC phosphate hydrate, the method further comprises adding a dialkyl phosphite (e.g., diethyl phosphite) and a trialkylamine base and mixing the resulting mixture at a temperature of 30-65°C.

[0052] In some embodiments, in combination with other above or below embodiments, the present invention relates to continuous manufacturing processes for producing PIPN HBr using PMEC phosphate, as shown in Scheme 5. Scheme 5

[0053] As shown in Scheme 5, PIPN is isolated as the hydrobromide salt. This differs from previous syntheses, in which PIPN is isolated as the hydrochloride salt, which inevitably results in mixtures of PIPN hydrobromide and PIPN hydrochloride. Thus, using HBr instead of HCl to form the corresponding PIPN salt allows for the production of only the PIPN HBr salt, which can be used just as easily and efficiently in subsequent synthetic processes. The flow-through process for obtaining PIPN HBr (as opposed to the batch method used to obtain PIPN HCl) enables the synthesis of the same desired intermediate while simultaneously reducing the number of device steps.

[0054] In some embodiments, step (a) is mixed in the presence of a polar aprotic solvent (e.g., acetonitrile), as described herein. In certain embodiments, step (a) is mixed in the presence of an acid. Illustrative suitable acids include, for example, acetic acid, trifluoroacetic acid (TFA), and mixtures thereof.

[0055] In some embodiments, in combination with other above or below embodiments, step (a) is heated (e.g., heated to at least 80°C, or from 80°C to 120°C, or from 80°C to 100°C). In some embodiments, step (a) is heated for a period of time, such as from 5 to 20 minutes (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 minutes). In some embodiments, step (a) is heated to 80°C for 15 minutes.

[0056] In some embodiments, step (b) and / or step (c) are mixed in the presence of a polar protic solvent (e.g., MeOH), as described herein. In some embodiments, step (b) is mixed in the presence of a base (e.g., a trialkylamine base). In some embodiments, the trialkylamine is diisopropylethylamine (Hunig's base).

[0057] In certain embodiments, step (b) is heated (e.g., heated to 50°C, or from 50°C to 80°C, or from 50°C to 60°C). In some embodiments, step (b) is heated to 50°C for 10 minutes.

[0058] In some embodiments, step (c) is heated (e.g., heated to 60°C, or from 60°C to 90°C, or from 60°C to 70°C). In some embodiments, step (c) is heated to 60°C for 10 minutes.

[0059] In some embodiments, prior to mixing the FNB, base, and PMEC phosphate hydrate in step (c), the method further comprises adding diethyl phosphite and a trialkylamine base and mixing the resulting mixture at a temperature of 30-65°C.PMEC

[0060] The disclosed methods for producing PIPN or a salt thereof involve the use of PMEC phosphate hydrate. In various embodiments, PMEC phosphate hydrate is produced by a method comprising (a) mixing piperazine and methyl chloroformate to form PMEC; (b) mixing PMEC with 0.5 molar equivalents of phosphoric acid to form PMEC phosphate hydrate; and (c) optionally filtering PMEC phosphate hydrate from the added impurity of step (b).

[0061] In some embodiments, step (a) is carried out in an aqueous solution and / or step (a) is carried out at a temperature of 20-55°C for a period of time (e.g., 1-12 h).

[0062] In some embodiments, in combination with other above or below embodiments, the disclosed methods for producing PIPN or a salt thereof further comprise isolating the PMEC formed in step (a) as a solution in a solvent selected from methylene chloride, dichloroethane, 2-methyltetrahydrofuran, and a mixture thereof. In some embodiments, the PMEC is isolated by (i) washing the resulting PMEC in step (a) with an organic solvent; (ii) modifying the pH to 8-14 by adding a base to form a basic aqueous solution; and (iii) extracting the PMEC from the basic aqueous solution of step (ii) with methylene chloride, dichloroethane, 2-methyltetrahydrofuran, or a mixture thereof.PIPA

[0063] In some embodiments, the present invention relates to methods for producing methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate (PIPA): (PIPA).

[0064] In various embodiments, the present invention relates to methods for producing PIPA from PIPN or a salt thereof prepared in accordance with the disclosed methods. In some embodiments, the present invention relates to methods for synthesizing PIPA comprising (a) mixing PIPN or a salt thereof, an aqueous solution of an inorganic base, and toluene to form a solution of PIPN free base; (b) hydrogenating the solution of PIPN free base in the presence of a palladium catalyst in a solvent comprising a solvent mixture of toluene and an alcohol to form crude PIPA, wherein the alcohol comprises ethanol or isopropanol; and (c) crystallizing PIPA from the crude PIPA in heptane and toluene.

[0065] In some embodiments, the inorganic base comprises sodium hydroxide.PCAR, APYR and NPYR

[0066] In some embodiments, the present invention relates to methods for phenyl (6-methylpyridin-3-yl) carbamate (PCAR) or a salt thereof (e.g., PCAR hydrochloride). The disclosed methods involve mixing 5-amino-2-methylpyridine (APYR) and phenyl chloroformate in acetonitrile to form PCAR or its salt, with mixing occurring in the absence of N-methyl-2-pyrrolidinone (NMP). In some embodiments, PCAR is formed as the hydrochloride salt.

[0067] In some embodiments, mixing is carried out at a temperature of 15-30°C for 1-15 hours.

[0068] In combination with other embodiments above or below, in some embodiments, the disclosed methods for synthesizing PCAR or a salt thereof further comprise, prior to mixing APYR and phenyl chloroformate, purifying APYR by a method comprising (i) washing an isopropyl acetate solution of crude APYR, wherein the crude APYR comprises up to 10 wt.% APYR hydrochloride, with aqueous sodium hydroxide, and mixing the washed APYR with charcoal to form an APYR solution after filtration; and (ii) crystallizing APYR from the APYR solution of step (i) from isopropyl acetate and heptane.

[0069] In some embodiments, in combination with other above or below embodiments, APYR is prepared by a process comprising (i) hydrogenating 2-methyl-5-nitropyridine (NPYR) in the presence of a palladium catalyst to form crude APYR; and (ii) crystallization of crude APYR from isopropyl acetate and heptane.

[0070] In some embodiments, NPYR is washed in isopropyl acetate with aqueous sodium hydroxide and then the washed NPYR in isopropyl acetate is mixed with charcoal prior to step (i).

[0071] In some embodiments, in combination with other above or below embodiments, the disclosed methods further comprise crystallizing the PCAR.OM

[0072] The present invention provides methods for producing OM (e.g., omecamtiv mecarbyl dihydrochloride monohydrate; "OM 2HCl H2O") from one or more intermediates (e.g., FNT, FNB, PIPN or a salt thereof, PIPA, PCAR, APYR and / or NPYR) obtained by the methods disclosed herein.

[0073] In some embodiments, the disclosed methods for producing OM dihydrochloride monohydrate comprise (a) mixing PIPA, PCAR, and a trialkylamine base in acetonitrile and tetrahydrofuran to form a solution of crude OM; (b) isolating OM free base from the solution of crude OM; and (c) mixing the isolated OM free base with 2-3 molar equivalents of hydrochloric acid in isopropanol and water to form OM dihydrochloride monohydrate.

[0074] The trialkylamine base is any suitable trialkylamine base as described herein.

[0075] In some embodiments, the isolation in step (b) comprises crystallizing the free base of omecamtiv mecarbil by adding water to the solution of crude omecamtiv mecarbil from step (a) and filtering the crystallized free base of omecamtiv mecarbil.

[0076] In some embodiments, the disclosed methods further comprise crystallizing omecamtiv mecarbyl dihydrochloride monohydrate from isopropanol and water.

[0077] In some embodiments, in combination with other above or below embodiments, the PCAR is produced according to the methods disclosed herein.

[0078] In some embodiments, the present invention relates to methods for producing omecamtiv mecarbyl dihydrochloride monohydrate, comprising (a) mixing PIPA, triphosgene and a trialkylamine in acetonitrile and tetrahydrofuran to form PIPA isocyanate; (b) mixing PIPA isocyanate and APYR to form OM free base, (c) mixing OM free base with 2-3 molar equivalents of hydrochloric acid in isopropanol and water to form OM dihydrochloride monohydrate.

[0079] In some embodiments, step (a) is carried out in a continuous manufacturing mode comprising mixing a first solution containing PIPA and a trialkylamine in acetonitrile and a second solution containing triphosgene in tetrahydrofuran using an on-chip micromixer and a reaction loop to form PIPA isocyanate.

[0080] In some embodiments, in combination with other above or below embodiments, step (b) is carried out in a continuous manufacturing mode comprising mixing a solution containing PIPA isocyanate and a solution containing AYPR using a Y-mixer and a reaction loop.

[0081] A number of the processes disclosed herein include steps noted as optional. In some cases, the optional step is not performed. In other cases, the optional step is performed. EMBODIMENTS 1. A method for synthesizing 2-fluoro-3-nitrotoluene ("FNT"), comprising mixing 2-fluorotoluene with one or more bases and a borating reagent to form a boronic acid; mixing the resulting boronic acid with iron nitrate or its hydrate to form FNT. 2. The method of embodiment 1, wherein the one or more bases comprise lithium diisopropylamide (LDA). 3. The method of embodiment 2, wherein LDA is added in the presence of diisopropylamine (DIPA). 4. The method of any one of embodiments 1-3, wherein step (a) is carried out in a polar aprotic solvent. 5. The method of embodiment 4, wherein the polar aprotic solvent comprises tetrahydrofuran (THF).6.The method of any one of embodiments 1-5, wherein step (b) is carried out in a non-polar solvent. 7. The method of embodiment 6, wherein the non-polar solvent comprises cyclohexane. 8. The method of any one of embodiments 1-7, wherein the iron nitrate is hydrated. 9. The method of embodiment 8, wherein the iron nitrate has the formula Fe(NO3)3*9H2O. 10. The method of any one of embodiments 1-9, further comprising treating the product of step (b) with a second base. 11. A method for synthesizing 2-fluoro-3-nitrotoluene ("FNT"), comprising mixing 2-fluorotoluene with one or more bases and a borating reagent to form a boronic acid; mixing the resulting boronic acid with nitric acid to form FNT. 12. The method of embodiment 11, wherein the one or more bases comprise lithium diisopropylamide (LDA).The method of embodiment 12 wherein LDA is added in the presence of diisopropylamine (DIPA). 14. The method of any one of embodiments 11-13 wherein step (a) is carried out in a polar aprotic solvent. 15. The method of embodiment 14 wherein the polar aprotic solvent comprises tetrahydrofuran (THF). 16. The method of any one of embodiments 11-15 wherein step (b) is carried out in a polar aprotic solvent. 17. The method of embodiment 16 wherein the polar aprotic solvent comprises 1,2-dichloroethane (DCE). 18. The method of embodiment 17 wherein DCE is present in an amount of 10 volumes relative to the borating reagent. 19. The method of any one of embodiments 11-18 wherein the nitric acid is 90% aqueous. 20. The method according to any one of embodiments 11-19, wherein the method further comprises heating the added impurity formed in step (b).21.The method of embodiment 20, wherein the added impurity is heated for at least 8 hours. 22. The method of embodiment 20 or 21, wherein the added impurity is heated to 70°C for at least 8 hours. 23. The method of any one of embodiments 11-22, further comprising adding water to the added impurity formed in step (b). 24. The method of embodiment 23, wherein 10 volumes of water are added relative to the borating reagent. 25. The method for synthesizing 1-(bromomethyl)-2-fluoro-3-nitrobenzene. (FNB), comprising (a) mixing 2-fluoro-3-nitrotoluene (FNT) with a brominating agent in the presence of a blue LED indicator to form a mixture of FNB and 1-(dibromomethyl)-2-fluoro-3-nitrobenzene (FNBr2);(b) mixing the FNB / FNBr2 mixture with a dialkyl phosphite to form FNB; and (c) optionally purifying the FNB formed in step (b) by (i) washing the FNB with a dialkyl phosphite and a trialkylamine or (ii) extracting the FNB with an organic solvent and washing with aqueous base.26. The method of Embodiment 25, wherein FNT is obtained by the method of any one of Embodiments 1-24.27. The method of Embodiment 25 or 26, wherein the organic solvent is toluene.28. The method of any one of Embodiments 25-27, wherein the base is sodium hydroxide.29. The method of any one of Embodiments 25-28, wherein the brominating agent is selected from N-bromosuccinimide.30. The method of any one of embodiments 25-29, wherein the dialkyl phosphite is selected from the group consisting of dimethyl phosphite, diethyl phosphite, and a combination thereof.31.The method of any one of embodiments 25-30, further comprising (d) mixing FNB, a trialkylamine base, and piperazine methyl carboxylate. ("PMEC") phosphate hydrate to form methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate (PIPN) or a salt thereof.32. The method of any one of embodiments 1-24, further comprising (c) mixing FNT, benzoyl peroxide, N-bromosuccinimide and acetic acid at a temperature of 70-95°C to form 1-(bromomethyl)-2-fluoro-3-nitrobenzene (FNB);(d) optionally extracting FNB with toluene, washing FNB with an aqueous basic solution, or both;(e) mixing FNB, a trialkylamine base, and piperazine methyl carboxylate ("PMEC") phosphate hydrate to form methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate (PIPN) or a salt thereof.33. The method of embodiment 32, wherein FNB is extracted with toluene and washed with aqueous sodium hydroxide prior to step (e).34. The method of any one of embodiments 31-33, wherein PIPN is formed as a hydrobromide salt.35. The method of any one of embodiments 31-34, wherein PMEC phosphate hydrate is prepared by a process comprising (a) mixing piperazine and methyl chloroformate to form PMEC; (b) mixing PMEC and 0.5 molar equivalents of phosphoric acid to form PMEC phosphate hydrate; and(c) optionally filtering PMEC phosphate hydrate from the added impurity of step (b).36. The method of embodiment 35 further comprising isolating the PMEC formed in step (a) as a solution in a solvent selected from methylene chloride, dichloroethane, 2-methyltetrahydrofuran, and mixtures thereof.37.The method of embodiment 36, wherein the isolation is carried out by (i) washing the obtained PMEC of step (a) with an organic solvent; (ii) modifying the pH to 8-14 by adding a base to form a basic aqueous solution; and (iii) extracting the PMEC from the basic aqueous solution of step (ii) with methylene chloride, dichloroethane, 2-methyltetrahydrofuran, or a mixture thereof. 38. The method of any of embodiments 35-37, wherein step (a) is carried out in an aqueous solution. 39. The method of any of embodiments 35-38, wherein step (a) is carried out at a temperature of from 20 to 55°C for 1-12 hours. 40. The method of any of embodiments 31-39, wherein the trialkylamine base comprises diisopropylethylamine or triethylamine. 41.The method of any one of embodiments 31-40, wherein prior to mixing FNB, the trialkylamine base, and PMEC phosphate hydrate, the method further comprises adding diethyl phosphite and the trialkylamine base and mixing the resulting mixture at a temperature of 30-65°C. 42. The method of any one of embodiments 31-41, further comprising (f) mixing PIPN or a salt thereof, an aqueous solution of an inorganic base, and toluene to form a solution of PIPN free base; (g) hydrogenating the solution of PIPN free base in the presence of a palladium catalyst in a solvent comprising toluene and an alcohol to form crude methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate (PIPA): (PIPA), wherein the alcohol comprises ethanol or isopropanol; and (h) crystallizing PIPA from crude PIPA in heptane and toluene. 43. The method of embodiment 42, wherein the crude base comprises sodium hydroxide. 44. The method of embodiment 42 or 43, further comprising (i) mixing PIPA, phenyl (6-methylpyridin-3-yl) carbamate (PCAR) and a trialkylamine base in acetonitrile and tetrahydrofuran to form a solution of crude omecamtiv mecarbil; (j) isolating omecamtiv mecarbil free base from the solution of crude omecamtiv mecarbil; and (k) mixing the isolated omecamtiv mecarbil free base with 2-3 molar equivalents of hydrochloric acid in isopropanol and water to form omecamtiv mecarbil dihydrochloride hydrate .45. The method of embodiment 44, wherein the trialkylamine base comprises diisopropylethylamine or triethylamine.46. The method of embodiment 44 or 45, wherein the isolation in step (h) comprises crystallizing omecamtiv mecarbil free base by adding water to the solution of crude omecamtiv mecarbil from step (g) and filtering the crystallized omecamtiv mecarbil free base.47. The method of any one of embodiments 44-46, further comprising crystallizing omecamtiv mecarbil dihydrochloride hydrate from isopropanol and water.48. The method of any one of embodiments 44-47, wherein PCAR or its salts are prepared by a method comprising mixing 5-amino-2-methylpyridine (APYR) and phenyl chloroformate in acetonitrile to form PCAR or a salt thereof, wherein the mixing is carried out in the absence of N-methyl-2-pyrrolidinone (NMP).49. The method of Embodiment 48, wherein the mixing is carried out at a temperature of 15-30°C for 1-15 hours.50. The method of Embodiment 48 or 49, wherein PCAR is formed as a hydrochloride salt.51. The method of any of Embodiments 48 to 50, wherein APYR is prepared by a method comprising (i) hydrogenating 2-methyl-5-nitropyridine (NPYR) in the presence of a palladium catalyst to form crude APYR; and (ii) crystallizing the crude material from isopropyl acetate and heptane. 52. The method of embodiment 51, further comprising, prior to step (i), washing NPYR in isopropyl acetate with aqueous sodium hydroxide, and then mixing the washed NPYR in isopropyl acetate with charcoal. 53. The method of any one of embodiments 48-52, further comprising, prior to mixing APYR and phenyl chloroformate, purifying APYR by a process comprising: (i) washing an isopropyl acetate solution of crude APYR, wherein the crude APYR comprises up to 10% by weight of APYR hydrochloride, with aqueous sodium hydroxide, and mixing the washed APYR with charcoal to form a solution of APYR after filtration; and(ii) crystallizing APYR from the APYR solution of step (i) from isopropyl acetate and heptane.54. The method of any one of embodiments 48-53, further comprising crystallizing PCAR.55.The method of embodiment 42 or 43, further comprising (i) mixing PIPA, triphosgene and a trialkylamine in acetonitrile and tetrahydrofuran to form PIPA isocyanate; (j) mixing PIPA isocyanate and 5-amino-2-methylpyridine. (APYR) to form omecamtiv mecarbil free base; and (k) mixing omecamtiv mecarbil free base with 2-3 molar equivalents of hydrochloric acid in isopropanol and water to form omecamtiv mecarbil dihydrochloride hydrate.56. The method of embodiment 55, wherein step (g) is carried out in a continuous manufacturing mode comprising mixing a first solution containing PIPA and a trialkylamine in acetonitrile and a second solution containing triphosgene in tetrahydrofuran using an on-chip micromixer and a reaction loop to form PIPA isocyanate.57. The method of embodiment 55 or 56, wherein step (h) is carried out in a continuous manufacturing mode comprising mixing a solution containing PIPA isocyanate and a solution containing AYPR using a Y-mixer and a reaction loop.58.A method for producing omecamtiv mecarbil or its salt, its hydrate or its salt hydrate, wherein the method comprises a method according to any one of embodiments 1-43.59. The method according to embodiment 58, wherein omecamtiv mecarbil, its salt, its hydrate or its salt hydrate is omecamtiv mecarbil dihydrochloride hydrate.EXAMPLES.

[0082] The following examples further illustrate the disclosed treatment methods, but, of course, they should not be construed as in any way limiting their scope.

[0083] The following abbreviations are used in the examples: PFR refers to plug flow reactor; CSTR refers to continuous stirred tank reactor; MTBE refers to methyl tert-butyl ether; NaOH refers to sodium hydroxide; LiCl refers to lithium chloride; EtOH refers to ethanol; and LCAP refers to liquid chromatography area percentage.

[0084] Example 1-1: Production of 2-fluoro-3-methylbenzeneboronic acid (2). This example provides a method for producing 2-fluoro-3-methylbenzeneboronic acid (i.e., boronic acid) according to an embodiment of the present invention.

[0085] A 2L four-necked round-bottomed flask was charged with 320mL THF and 154.3g diisopropylamine. The resulting mixture was cooled to -15°C and stirred. Then, 582mL-BuLi (2.5M in hexane) was added dropwise under a nitrogen atmosphere while maintaining the temperature below -10°C. After the addition was complete, the reaction mixture was stirred for 30 min at -15°C and then cooled to -35°C. Then, a solution of 80g 2-fluorotoluene (1) in 160mL THF was added dropwise while maintaining the temperature below -30°C. The resulting mixture was then stirred for 1 h at -35°C. Then, 158.5g trimethyl borate was added to the reaction mixture while maintaining the temperature below -30°C (an exothermic reaction was observed). The reaction mixture was stirred for 2 h at -35°C and then allowed to warm to room temperature.

[0086] The reaction was quenched by pouring 658 g of water and 343 g of 30% HCl into an HCl solution while maintaining the temperature below 30°C. The resulting mixture was extracted with MTBE (3×160 mL). The organic layers were combined, and a 1 M NaOH / H2O solution was added until pH > 10. The aqueous layer was then washed once with 160 mL of MTBE. To the aqueous layer, 240 mL of MTBE and a 1 M HCl solution were added until pH in the aqueous layer reached 1. The aqueous layer was then further extracted with MTBE (2×240 mL). The resulting organic layers were combined, washed once with 160 mL of water, and then concentrated to obtain 2 as a white powder, which was used directly in the next reaction.

[0087] Example 1-2: Production of 2-fluoro-3-nitrotoluene (FNT) (3) This example provides a method for producing FNT according to an embodiment of the present invention.

[0088] In a 1 L four-necked round-bottomed flask, the product 2 obtained in Example 1-1 was added to a mixture of 4 volumes of cyclohexane and 100 g (0.5 equiv.) of ferric nitrate (Fe(NO3)3 9H2O). The resulting reaction mixture was stirred at 65-75°C for 12 hours. The reaction progress was monitored by HPLC until less than 5% of compound 2 appeared, after which the reaction mixture was cooled to room temperature and filtered. The filter cake was washed with cyclohexane. The combined filtrate was then washed with 2 x 150 mL of 5% NaOH (aq.) and then with 1 x 150 mL of water. The filtrate was concentrated and then distilled (e.g., 110-115°C at 40-60 mmHg) to yield 38-42 g of FNT (3).

[0089] Example 2-1: Flow-through production of 2-fluoro-3-methylbenzeneboronic acid (2). This example provides a method for producing 2-fluoro-3-methylbenzeneboronic acid (i.e., boronic acid) according to an embodiment of the present invention.

[0090] The flow chemistry setup is described in Figure 1. Feedstock A (THF) and feedstock B (DIPA) were combined through a T-mixer with relative flow rates as described below. A subsequent T-mixer combined the resulting stream with feedstock C, and lithiation occurred in a PFR with a residence time of 5 min and a bath temperature of -40 to -10°C. The resulting mixture was passed to two continuous stirred tank reactors (CSTRs) in series with a residence time of 12-14 min each, maintaining an internal temperature of -5 to 30°C. The resulting solution was collected under nitrogen and was a solution of approximately 1.5 M LDA in THF / hexanes (Table 1). Table 1. Preparation of LDA Raw materials Reagent Relative flow (g / min) Mass flow (ml / min) Relative flow (ml / min) Equ. A THF 1,207 1,36 1,00 B DIPA 1 1,39 1,03 1 C n-BuLi (2.5 M) in hexanes 2,814 4,06 2,99 1,03 Final conc. LDA (M) 1,4896

[0091] The flow chemistry setup for the borylation procedure is illustrated in Figure 2 under the conditions shown in Table 2. Feedstock A and feedstock B were fed into continuous stirred tank reactor 1 (CSTR 1) (internal temp.=-10-35°C) at a relative flow rate of 1:1.255 g / min (A:B) and a target residence time of approximately 40 min. The overflow from CSTR 1 was fed to CSTR 2 (internal temp. 0-30°C, residence time of approximately 40 min) and finally to CSTR 3 (internal temp. 0-30°C, residence time=~30 min). Feedstock C was fed to CSTR 3 at a relative flow rate of 1.40 g / min. Table 2 - Borylation Procedure Raw materials Reagent Equ. Weight (kg / kg) Volumes (l / kg) Relative flow (g / min) Relative flow (ml / min) Equ. A LDA from stage 1 1,255 density 2,33 B 2-F-toluene 1 1 --- 1 density 1 B(OEt)3 3,8 5,037 5,871 THF 6 rev. 5,32 6 C HCl (36 wt.%) 8,15 6,91 1,4 density 12,075 H2O 15 15 Relative relation to ( 2 ) Exit Boric acid 2,8 EtOH 2,8 DIPA 2,33 LiCl 2,33 THF 6 rev. H2O 15 rev. HCl 6 vol. H2O + 6 equiv. HCl

[0092] Batch isolation: The reaction mixture was quenched in 4 M aqueous HCl solution (15~20 vol) at 30°C, the mixture was separated, and the aqueous phase was extracted with MTBE (3 × 5 vol). The organic phases were combined and pH was adjusted with 10% NaOH / H2O until pH was greater than 10. The aqueous phase was washed with MTBE (1 × 3 vol). Then, MTBE (5 vol) was added to the aqueous phase and adjusted with 1 M HCl until pH = 1-3. The resulting aqueous phase was extracted with MTBE (2 × 5 vol). The resulting organic phase was combined and washed once with water (3 vol). Then, the organic phase was concentrated to 1~1.5 vol, water (5 vol) was added for crystallization, and the reaction mixture was cooled to 0-10°C. After stirring for 2 h, the mixture was filtered and washed with water (2 vol). The crude solid was suspended with heptane (3 vol) for 1~3 h, then the mixture was filtered and washed with heptane (1 vol).The solid was dried with nitrogen at below 35°C to give 2-fluorotolueneboronic acid as an off-white to light yellow powder.

[0093] Example 2-2: Preparation of 2-fluoro-3-nitrotoluene (FNT) (3) using nitric acid

[0094] Reactor 1 was charged with 2-fluoro-3-methylbenzeneboronic acid (2). A NaOH scrubber was also installed in Reactor 1 to suppress the evolution of NO2 gas. Then, 1,2-dichloroethane (10 vol.) was added to Reactor 1 at room temperature, stirring was started, and the reactor contents were heated to 70°C. After the temperature in Reactor 1 reached 70°C ± 5°C, HNO3 (fuming, 90%, 1.3 equiv.) was charged into the reactor. The reaction mixture was then stirred at 70°C ± 5°C for 8 h.

[0095] The reaction contents were allowed to cool to 20°C. Water (10 vol) was added to reactor 1 and stirred for 30 min. Then, the contents of reactor 1 were passed through a cleaning filter and the aqueous phase was collected. Then, an aqueous solution of sodium bicarbonate (10 vol) was added, stirred for 30 min and the aqueous phase was collected. Then, another aqueous solution of sodium bicarbonate (10 vol) was added, stirred for 30 min and the aqueous phase was collected. Then, the solvent in the organic phase was changed from 1,2-dichloroethane to MeOH (8 vol). Norix-SX1 charcoal (2.5 wt%) was added and stirred for 2 hours. The contents of the reactor were filtered to remove charcoal, and the filter was washed with MeOH (2 vol). The contents of reactor 1 were cooled to 10°C and water (5 vol.) was added over 3 h, maintaining the temperature at 10°C. The contents of reactor 1 were maintained at 10°C for 30 min and then cooled to 1-3°C.The solid contents of reactor 1 were then isolated by filtration and washed with a 1:1 MeOH / water mixture pre-cooled to 3°C. The resulting solid was dried in vacuo at 3°C ​​for 16 h and isolated3 as a pale yellow solid.

[0096] Alternative distillation purification: 1,2-dichloroethane was then removed by concentration under reduced pressure. The resulting brown oil was purified by distillation at 35 Torr. The product was distilled at 110-120°C and the appropriate fractions were collected to yield a light green liquid, which solidified at room temperature to form a white solid. Example 3: Flow-through preparation of PIPN HBr from FNT

[0097] This example shows a flow chemical process according to an embodiment of the present invention.

[0098] FNT stock solution (3) was prepared by dissolving 100 g (647 mmol) of FNT in 1087 mL of acetonitrile and 12 mL (161 mmol, 0.25 equiv) of trifluoroacetic acid. Under the presence of a blue LED indicator, NBS (143 g, 806 mmol, 1.25 equiv) was then added with stirring until the solution became homogeneous.

[0099] A stock solution of diethyl phosphite was prepared by dissolving 33 ml (258 mmol, 0.40 eq.) diethyl phosphite in 100 ml MeOH and 73 ml (418 mmol, 2.5 eq.)N,N-diisopropylethylamine.

[0100] The stock solution of PMEC phosphate was prepared by dissolving 144 g (648 mmol, 1.0 equiv) of PMEC phosphate in 300 mL of MeOH and 281 mL (1611 mmol, 2.5 equiv) of N,N-diisopropylethylamine. The liquid suspension was then filtered, and the filter was washed with 100 mL of MeOH.

[0101] The feed solutions were then pumped through the flow process unit at a rate of 2.85 mL / min for the FNT solution, 0.46 mL / min for the diethyl phosphite solution, and 1.62 mL / min for the PMEC phosphate solution, as shown in Figure 3. All reaction loops were heated in thermostatically controlled water baths.

[0102] The above setup was operated for approximately 4 hours, periodically collecting fractions. A summary of the concentration data for the crude PIPN stream is shown in Figure 4. Fractions 11-14 (~600 mL) were collected for crystallization.

[0103] For crystallization, a seed bed was prepared by adding 80 mL of acetonitrile and 1.39 g of PIPN HBr to a 2 L ChemGlass reactor and heating to 60°C. The crude PIPN solution was then added at a rate of 300 mL / h along with concentrated HBr solution at 26 mL / h. After complete addition, the slurry was maintained at 60°C for 2 hours, then cooled to 25°C over 30 minutes and maintained at this temperature for another 60 minutes.

[0104] The slurry was then filtered and the solids were washed with 3 x 4 vol. acetonitrile at 55°C. The material was then dried under a stream of nitrogen. 53.55 g of PIPN HBr were recovered (yield 76%), representing 99.9 LCAP and 97.3 wt% purity.

[0105] The above examples are merely illustrative of embodiments of the disclosed methods described herein and are not intended to limit the disclosed methods. Variations and changes obvious to those skilled in the art should fall within the scope and spirit of the present invention, which are defined in the appended claims.

[0106] All references, including publications, patent applications, and patents, cited in this document are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and set forth herein in its entirety.

[0107] The use of the singular forms "a," "an," and "at least one" and similar references in the context of describing embodiments of the present invention (especially in the context of the following claims) shall be construed as encompassing both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context. The use of the term "at least one" followed by a list of one or more elements (e.g., "at least one of A and B") shall be understood to mean one element selected from the listed elements (A or B), or any combination of two or more of the listed elements (A and B), unless otherwise indicated herein or clearly contradicted by the context. The terms "comprising," "having," "including," and "containing" shall be construed as open-ended terms (i.e., meaning "including without limitation"), unless otherwise indicated herein.The recitation of ranges of values ​​in this document is intended merely to serve as a shorthand method of referring to each individual value falling within the range, unless otherwise stated herein, and each individual value is included in the description as if it were individually recited herein. All methods described in this document may be performed in any suitable order unless otherwise stated herein or clearly contradicted by context. The use of any and all examples or illustrative language (e.g., "such as") provided herein is intended only to better illustrate embodiments of the present invention and does not limit the scope of the invention unless otherwise stated. No language in the description should be construed as indicating any unreported element as essential to the practice of the invention.

Claims

1. A method for synthesizing 2-fluoro-3-nitrotoluene (FNT), comprising: (a) mixing 2-fluorotoluene with one or more bases and a borating reagent to form a boronic acid; and (b) mixing the obtained boronic acid with iron nitrate or its hydrate to form FNT.

2. The method of claim 1, wherein one or more bases comprises lithium diisopropylamide (LDA).

3. The method according to claim 2, wherein LDA is added in the presence of diisopropylamine (DIPA).

4. The method according to any one of claims 1 to 3, wherein step (a) is carried out in a polar aprotic solvent.

5. The method of claim 4, wherein the polar aprotic solvent comprises tetrahydrofuran (THF).

6. The method according to any one of claims 1 to 5, wherein step (b) is carried out in a non-polar solvent.

7. The method of claim 6, wherein the non-polar solvent comprises cyclohexane.

8. The method according to any one of claims 1 to 7, wherein the iron nitrate is hydrated.

9. The method according to claim 8, wherein the iron nitrate has the formula Fe(NO3)3⋅9H2O.

10. The method according to any one of claims 1 to 9, further comprising treating the product of step (b) with a second base.

11. Method for the synthesis of 1-(bromomethyl)-2-fluoro-3-nitrobenzene (FNB), including: (a) mixing 2-fluoro-3-nitrotoluene (FNT) with a brominating agent in the presence of a blue LED indicator to form a mixture of FNB and 1-(dibromomethyl)-2-fluoro-3-nitrobenzene (FNBr2), wherein 2-fluoro-3-nitrotoluene (FNT) is obtained by the method according to any one of paragraphs 1-10; (b) mixing the FNB / FNBr2 mixture with a dialkyl phosphite to form FNB; and (c) optionally purifying the FNB formed in step (b) by (i) washing the FNB with a dialkyl phosphite and a trialkylamine or (ii) extracting the FNB with an organic solvent and washing with an aqueous base.

12. The method according to claim 11, wherein the organic solvent is toluene.

13. The method according to any one of claims 11 or 12, wherein the base is sodium hydroxide.

14. The method according to any one of claims 11 to 13, wherein the brominating agent is selected from N-bromosuccinimide.

15. The method according to any one of claims 11-14, wherein the dialkyl phosphite is selected from the group consisting of dimethyl phosphite, diethyl phosphite, and a combination thereof.

16. Method for the synthesis of methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate (PIPN) or its salts, including (d) mixing FNB, trialkylamine base and piperazine methyl carboxylate phosphate hydrate (PMEC) to form methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate (PIPN) or its salts, wherein FNB is obtained by the method according to any of paragraphs 11-15.

17. Method for the synthesis of methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate (PIPN) or its salts, including: (c) mixing FNT, benzoyl peroxide, N-bromosuccinimide and acetic acid at 70-95°C to form 1-(bromomethyl)-2-fluoro-3-nitrobenzene (FNB), where FNT is obtained by the method according to any of paragraphs 1-10; (d) optionally extracting FNB with toluene, washing FNB with an aqueous base solution, or both; (e) mixing FNB, trialkylamine base and piperazine methyl carboxylate phosphate hydrate (PMEC) to form methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate (PIPN) or its salts.

18. The method of claim 17, wherein the FNB is extracted with toluene and washed with aqueous sodium hydroxide prior to step (e).

19. The method according to any one of claims 16 to 18, wherein PIPN is formed as a hydrobromide salt.

20. The method according to any one of claims 16 to 19, wherein the PMEC phosphate hydrate is obtained by a method comprising: (a) mixing piperazine and methyl chloroformate to obtain PMEC; (b) mixing PMEC and 0.5 molar equivalents of phosphoric acid to form PMEC phosphate hydrate; and (c) optionally filtering the PMEC phosphate hydrate from the impurity of step (b).

21. The method of claim 20, further comprising isolating the PMEC formed in step (a) as a solution in a solvent selected from methylene chloride, dichloroethane, 2-methyltetrahydrofuran, and mixtures thereof.

22. The method according to claim 21, wherein the isolation is carried out by (i) washing the obtained PMEC in step (a) with an organic solvent; (ii) modifying the pH to 8-14 by adding a base to form a basic aqueous solution; and (iii) extracting PMEC from the basic aqueous solution of step (ii) with methylene chloride, dichloroethane, 2-methyltetrahydrofuran or a mixture thereof.

23. The method according to any one of claims 20 to 22, wherein step (a) is carried out in an aqueous solution.

24. The method according to any one of claims 20 to 23, wherein step (a) is carried out at a temperature of from 20 to 55°C for 1 to 12 hours.

25. The method according to any one of claims 16 to 24, wherein the trialkylamine base comprises diisopropylethylamine or triethylamine.

26. The method according to any one of claims 16-25, wherein before mixing FNB, trialkylamine base and PMEC phosphate hydrate, the method further comprises adding diethyl phosphite and trialkylamine base and mixing the resulting mixture at a temperature of 30-65°C.

27. Method for the synthesis of methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate (PIPA), including: (f) mixing PIPN or a salt thereof, an aqueous solution of an inorganic base and toluene to form a solution of PIPN free base, wherein the PIPN is obtained by the method of any one of claims 16 to 26; (g) hydrogenation of a solution of the free base of PIPN in the presence of a palladium catalyst in a solvent containing toluene and an alcohol to form crude methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate (PIPA), where alcohol includes ethanol or isopropanol; and (h) crystallizing PIPA from crude PIPA in heptane and toluene.

28. The method of claim 27, wherein the inorganic base comprises sodium hydroxide.

29. Method for synthesizing omecamtiv mecarbil dihydrochloride hydrate , including: (i) mixing PIPA, phenyl (6-methylpyridin-3-yl) carbamate (PCAR) and a trialkylamine base in acetonitrile and tetrahydrofuran to form a solution of crude omecamtiv mecarbil, wherein (PIPA) is obtained by the method of any one of claims 27, 28; (j) isolating the free base of omecamtiv mecarbil from the solution of crude omecamtiv mecarbil; and (k) mixing the isolated free base of omecamtiv mecarbil with 2-3 molar equivalents of hydrochloric acid in isopropanol and water to form omecamtiv mecarbil dihydrochloride hydrate .

30. The method of claim 29, wherein the trialkylamine base comprises diisopropylethylamine or triethylamine.

31. The method of claim 29 or 30, wherein the isolation in step (j) comprises crystallizing the free base of omecamtiv mecarbil by adding water to the solution of crude omecamtiv mecarbil from step (i) and filtering the crystallized free base of omecamtiv mecarbil.

32. The method according to any one of claims 29-31, further comprising crystallizing omecamtiv mecarbil dihydrochloride hydrate from isopropanol and water.

33. The method according to any one of claims 29 to 32, wherein PCAR or a salt thereof is obtained by a method comprising mixing 5-amino-2-methylpyridine (APYR) and phenyl chloroformate in acetonitrile to form PCAR or its salt, with mixing being carried out in the absence of N-methyl-2-pyrrolidinone (NMP).

34. The method according to claim 33, wherein mixing is carried out at a temperature of 15-30°C for 1-15 hours.

35. The method according to claim 33 or 34, wherein PCAR is formed as a hydrochloride salt.

36. The method according to any one of paragraphs 33-35, wherein APYR is obtained by a method comprising: (i) hydrogenation of 2-methyl-5-nitropyridine (NPYR) in the presence of a palladium catalyst to form crude APYR; and (ii) crystallization of the crude material from isopropyl acetate and heptane.

37. The method of claim 36, further comprising, prior to step (i), washing NPYR in isopropyl acetate with aqueous sodium hydroxide and then mixing the washed NPYR in isopropyl acetate with charcoal.

38. The method according to any one of paragraphs 33-37, further comprising, before mixing the APYR and phenyl chloroformate, purifying the APYR by a method comprising: (i) washing an isopropyl acetate solution of crude APYR, the crude APYR containing up to 10% by weight of APYR hydrochloride, with aqueous sodium hydroxide and mixing the washed APYR with charcoal to form an APYR solution after filtration; and (ii) crystallization of APYR from the APYR solution of step (i) from isopropyl acetate and heptane.

39. The method according to any one of claims 33-38, further comprising crystallizing the PCAR.

40. Method for synthesizing omecamtiv mecarbil dihydrochloride hydrate , including: (i) mixing PIPA, triphosgene and a trialkylamine in acetonitrile and tetrahydrofuran to form PIPA isocyanate, wherein (PIPA) is obtained by the method of any one of claims 27, 28; (j) mixing PIPA isocyanate and 5-amino-2-methylpyridine (APYR) to form the free base omecamtiv mecarbil; and (k) mixing omecamtiv mecarbil free base with 2-3 molar equivalents of hydrochloric acid in isopropanol and water to form omecamtiv mecarbil dihydrochloride hydrate.

41. The method of claim 40, wherein step (i) is carried out by continuous production comprising mixing a first solution containing PIPA and a trialkylamine in acetonitrile and a second solution containing triphosgene in tetrahydrofuran using a micromixer chip and a reaction loop to form PIPA isocyanate.

42. The method according to claim 40 or 41, wherein step (j) is carried out by continuous production comprising mixing a solution containing PIPA isocyanate and a solution containing AYPR using a Y-mixer and a reaction loop.

43. A method for producing omecamtiv mecarbil or its salt, its hydrate or a hydrate of its salt, wherein the method includes the method according to any one of claims 1-28.

44. The method according to claim 43, wherein omecamtiv mecarbil, its salt, its hydrate or hydrate of its salt is omecamtiv mecarbil dihydrochloride hydrate.

Images